The Life Sciences team advised BridgeBio Pharma (Nasdaq: BBIO) on the completion of a $200 million private financing of its former subsidiary, TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) to accelerate the development of its oncology portfolio. The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood Fund.
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials.
The Goodwin team was led by Maggie Wong, Kimberley Maruncic, Larissa Pinho, Laura Garvey and Leon Levman and included Emily Beman, Christopher Zhong (IPTS/Licensing), Gozde Guckaya (Global Trade), Mark Burnett (Opinions) and paralegals Pat Robichaud and Christina Keeney.
For additional details on the financing, please read the press release.